ITEM VIEW

Bacteremia in human immunodeficiency virus-infected children in Cape Town, South Africa

dc.contributor.authorLe Roux D.M.
dc.contributor.authorCotton M.F.
dc.contributor.authorLe Roux S.M.
dc.contributor.authorWhitelaw A.
dc.contributor.authorLombard C.J.
dc.contributor.authorZar H.J.
dc.date.accessioned2011-10-13T16:58:23Z
dc.date.available2011-10-13T16:58:23Z
dc.date.issued2011
dc.identifier.citationPediatric Infectious Disease Journal
dc.identifier.citation30
dc.identifier.citation10
dc.identifier.citationhttp://www.scopus.com/inward/record.url?eid=2-s2.0-80052950552&partnerID=40&md5=b9d9398a50fcbe4a3f6c3d4b3e34b1db
dc.identifier.issn8913668
dc.identifier.other10.1097/INF.0b013e318220a68b
dc.identifier.urihttp://hdl.handle.net/10019.1/16705
dc.description.abstractBacteremia contributes to morbidity of HIV-infected children. In a randomized controlled trial evaluating trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis, 47 bacteremias were detected. The incidence rate of bacteremia increased in the first 3 months after starting combination antiretroviral therapy (cART), but decreased by 74% once children were established on cART for more than 3 months. Children should be prioritized for early cART. Copyright © 2011 by Lippincott Williams & Wilkins.
dc.subjectAfrica
dc.subjectantiretroviral therapy
dc.subjectbacteremia
dc.subjectchildren
dc.subjectHIV
dc.subjectpreventive therapy
dc.subjecttrimethoprim- sulfamethoxazole
dc.titleBacteremia in human immunodeficiency virus-infected children in Cape Town, South Africa
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW